CCL2 and neoplasm: Dimethyl itaconate decreases CCL2 production in epithelial cells, reduces macrophage recruitment to the tumor microenvironment, alleviates the hyperinflammatory state of UC, and lowers the risk of colitis-associated cancer (159).